O
Olufemi Adelakun
Researcher at Bristol-Myers Squibb
Publications - 5
Citations - 164
Olufemi Adelakun is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Immunotherapy & Cancer. The author has an hindex of 2, co-authored 5 publications receiving 125 citations.
Papers
More filters
Journal ArticleDOI
Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression
David J. Donnelly,R. Adam Smith,Paul E. Morin,Dasa Lipovsek,Jochem Gokemeijer,Daniel Cohen,Virginie Lafont,Tritin Tran,Erin L. Cole,Martin C. Wright,Joonyoung Kim,Adrienne Pena,Daniel W. Kukral,Douglas D. Dischino,Patrick L Chow,Jinping Gan,Olufemi Adelakun,Xi-Tao Wang,Kai Cao,David Leung,Samuel J. Bonacorsi,Wendy Hayes +21 more
TL;DR: The feasibility of noninvasively imaging the PD-L1 status of tumors by small-animal PET studies is demonstrated by 18F-BMS-986192, which bound to tumor tissues as a function of PD- L1 expression determined by immunohistochemistry.
Patent
Anti-gitr antibodies for cancer diagnostics
Xi-Tao Wang,Olufemi Adelakun,Anne Lewin,Korman Alan J,Mark Selby,Changyu Wang,Haichun Huang,Karla A. Henning,Nils Lonberg,Mohan Srinivasan,Michelle Minhua Han,Guodong Chen,Huang Richard Y,Indrani Chakraborty,Susan Chien-Szu Wong,Huiming Li +15 more
TL;DR: In this article, diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR) are used for methods of detecting the expression of GITR in biological samples, for example, tumor tissue.
Journal ArticleDOI
Antipeptide Immunocapture with In-Sample Calibration Curve Strategy for Sensitive and Robust LC-MS/MS Bioanalysis of Clinical Protein Biomarkers in Formalin-Fixed Paraffin-Embedded Tumor Tissues.
Naiyu Zheng,Kristin Taylor,Huidong Gu,Rasa Santockyte,Xi-Tao Wang,Jean McCarty,Olufemi Adelakun,Yan J Zhang,Renuka Pillutla,Jianing Zeng +9 more
TL;DR: This approach demonstrated the feasibility to quantify low abundant protein biomarkers in FFPE tissues with improved sensitivity, specificity, and robustness and showed great potential as an orthogonal analytical approach to IHC for clinical applications.
Proceedings ArticleDOI
Abstract 6694: Highly selective anti-CCR8 antibody-mediated depletion of regulatory T cells leads to potent antitumor activity alone and in combination with anti-PD-1 in preclinical models
Ruth Y. Lan,Amy Jhatakia,Joseph R Campbell,Nathan O. Siemers,Kai Lu,Mohammed Nasser,Tetiana Grigoriev,Priti B. Singh,Logan M Vlach,Tim Sproul,Chengyue Zhang,Xi-Tao Wang,Olufemi Adelakun,Felix Findeisen,Pavel Strop,Arvind Rajpal,Natalie Bezman,Michael Quigley,Renu Jain +18 more
TL;DR: The results support further clinical evaluation of CCR8 depletion in combination with immune checkpoint blockade as a novel immunotherapy for cancer.
Patent
Anticorps anti-gitr pour le diagnostic du cancer
Xi-Tao Wang,Olufemi Adelakun,Anne Lewin,Korman Alan J,Mark Selby,Changyu Wang,Haichun Huang,Karla A. Henning,Nils Lonberg,Mohan Srinivasan,Michelle Minhua Han,Guodong Chen,Huang Richard Y,Indrani Chakraborty,Susan Chien-Szu Wong,Huiming Li +15 more
TL;DR: La presente invention concerne des anticorps de diagnostic qui se lient au recepteur du facteur de necrose tumorale induit par des glucocorticoides (GITR) dans les methodes de detection de l'expression de GITR dans des echantillons biologiques.